Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory Board
March 21, 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is honored to...
Vivacitas Oncology, Inc. and Image Analysis Group to Present on AR-67 Clinical Response Evaluation at the Society for Neuro-Oncology Annual Conference
November 18, 2021 08:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Vivacitas Oncology, a privately-held oncology company focused on tough-to-treat cancers, and Image Analysis Group (IAG), a premier...
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
October 24, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18
November 09, 2017 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Nov. 09, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...